Literature DB >> 28721853

uS10, a novel Npro-interacting protein, inhibits classical swine fever virus replication.

Huifang Lv1, Wang Dong1, Gui Qian1, Jie Wang1, Xiaomeng Li1, Zhi Cao2, Qizhuang Lv3, Chengbao Wang1, Kangkang Guo1, Yanming Zhang1.   

Abstract

Classical swine fever (CSF) is a severe, febrile and highly contagious disease caused by classical swine fever virus (CSFV) that has resulted in huge economic losses in the pig industry worldwide. CSFV Npro has been actively studied but remains incompletely understood. Few studies have investigated the cellular proteins that interact with Npro and their participation in viral replication. Here, the yeast two-hybrid (Y2H) system was employed to screen Npro-interacting proteins from a porcine alveolar macrophage (PAM) cDNA library, and a blast search of the NCBI database revealed that 15 cellular proteins interact with Npro. The interaction of Npro with ribosomal protein S20, also known as universal S10 (uS10), was further confirmed by co-immunoprecipitation and glutathione S-transferase pull-down assays. Furthermore, uS10 overexpression inhibited CSFV replication, whereas the knockdown of uS10 promoted CSFV replication in PAMs. In addition, Npro or CSFV reduced uS10 expression in PAMs in a proteasome-dependent manner, indicating that Npro-uS10 interaction might contribute to persistent CSFV replication. Our previous research showed that CSFV decreases Toll-like receptor 3 (TLR3) expression. The results showed that uS10 knockdown reduced TLR3 expression, and that uS10 overexpression increased TLR3 expression. Notably, uS10 knockdown did not promote CSFV replication following TLR3 overexpression. Conversely, uS10 overexpression did not inhibit CSFV replication following TLR3 knockdown. These results revealed that uS10 inhibits CSFV replication by modulating TLR3 expression. This work addresses a novel aspect of the regulation of the innate antiviral immune response during CSFV infection.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28721853     DOI: 10.1099/jgv.0.000867

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  7 in total

Review 1.  Fatal attraction: The roles of ribosomal proteins in the viral life cycle.

Authors:  Clare M Miller; Sangeetha Selvam; Gabriele Fuchs
Journal:  Wiley Interdiscip Rev RNA       Date:  2020-07-12       Impact factor: 9.957

2.  FHC, an NS4B-interacting Protein, Enhances Classical Swine Fever Virus Propagation and Acts Positively in Viral Anti-apoptosis.

Authors:  Gui Qian; Huifang Lv; Jihui Lin; Xiaomeng Li; Qizhuang Lv; Tao Wang; Jing Zhang; Wang Dong; Kangkang Guo; Yanming Zhang
Journal:  Sci Rep       Date:  2018-05-29       Impact factor: 4.379

3.  Tumor Necrosis Factor Receptor-Associated Factor 5 Interacts with the NS3 Protein and Promotes Classical Swine Fever Virus Replication.

Authors:  Huifang Lv; Wang Dong; Kangkang Guo; Mingxing Jin; Xiaomeng Li; Cunfa Li; Yanming Zhang
Journal:  Viruses       Date:  2018-06-05       Impact factor: 5.048

Review 4.  Regulation of Ribosomal Proteins on Viral Infection.

Authors:  Shuo Li
Journal:  Cells       Date:  2019-05-27       Impact factor: 6.600

5.  Ribosomal proteins as a possible tool for blocking SARS-COV 2 virus replication for a potential prospective treatment.

Authors:  Marian Rofeal; Fady Abd El-Malek
Journal:  Med Hypotheses       Date:  2020-05-30       Impact factor: 1.538

6.  RPLP1, an NS4B-interacting protein, enhances production of CSFV through promoting translation of viral genome.

Authors:  Longxiang Zhang; Jihui Lin; Maoyang Weng; Ying Wen; Yanming Zhang; Wen Deng
Journal:  Virulence       Date:  2022-12       Impact factor: 5.882

7.  Classical Swine Fever Virus Infection and Its NS4A Protein Expression Induce IL-8 Production through MAVS Signaling Pathway in Swine Umbilical Vein Endothelial Cells.

Authors:  Wang Dong; Huifang Lv; Kangkang Guo; Tao Wang; Yueling Ouyang; Mingxing Jin; Yanming Zhang
Journal:  Front Microbiol       Date:  2018-01-12       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.